ArticleKidney international reports2025
Pilot Randomized Trial of Dialysis Less Frequently in the Elderly: The DLITE Study.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07738731 (A Randomized Controlled Study of Dialysis Less Frequently in the Elderly), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Study of Dialysis Less Frequently in the Elderly
Who cites it
4 citing papers in PubMed.
- Response to the Letter to the Editor Entitled "Twice- Versus Thrice-Weekly Hemodialysis in the Elderly: Are we 'DLITE'd?Kidney international reports · 2026Article
- Twice- Versus Thrice-Weekly Hemodialysis in the Elderly: Are we 'DLITE'd?Kidney international reports · 2026Article
- Perspectives on Quality of Life, Vascular Access, and Fluid Balance in Incremental Hemodialysis: A Narrative Review.Kidney360 · 2026Review
- New RCTs Advance Incremental Dialysis With Clinically-Guided HD and HDF-Based Prescriptions.Kidney international reports · 2025Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The elderly represent the most rapidly growing age group with end-stage kidney disease (ESKD) world-wide. The hemodialysis (HD) prescription that provides the best outcomes for this distinct population with reduced life expectancy is unknown. The primary objective of the DLITE pilot trial was to determine the feasibility and safety of conducting a trial designed to determine whether twice versus thrice weekly HD improves quality of life (QOL) and important clinical outcomes in elderly patients with HD. Methods: We conducted a pilot single-center open randomized controlled trial (RCT) of patients aged ≥ 70 years of age who are on incident HD. Subjects were randomized to twice ( Results: Recruitment rate was 1.1 patients/mo. The consent rate of eligible subjects was high (77%), adherence was ≥ 99%, 96% of QOL surveys were completed, and 78% of randomized subjects completed the study. Pre-HD normokalemia rates for twice versus thrice weekly were 89% and 90%, respectively. Urgent HD treatments for hypervolemia and hyperkalemia, hospitalizations, and death were infrequent in both arms. Conclusion: The results of this pilot RCT of twice versus thrice weekly HD in elderly patients on incident HD reveal that the study intervention was feasible and safe. These results will inform the design of a multicenter RCT with QOL, economic, morbidity, and mortality end points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.